Clene/$CLNN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Clene
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Ticker
$CLNN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
76
ISIN
US1856342019
Website
Clene Metrics
BasicAdvanced
$38M
-
-$3.85
0.48
-
Price and volume
Market cap
$38M
Beta
0.48
52-week high
$8.60
52-week low
$2.28
Average daily volume
118K
Financial strength
Current ratio
1.363
Quick ratio
0.913
Long term debt to equity
-338.528
Total debt to equity
-421.094
Interest coverage (TTM)
-8.15%
Management effectiveness
Return on assets (TTM)
-49.62%
Return on equity (TTM)
8,200.56%
Valuation
Price to revenue (TTM)
90.66
Price to book
-7.32
Price to tangible book (TTM)
-7.32
Price to free cash flow (TTM)
-1.648
Growth
Revenue change (TTM)
-43.55%
Earnings per share change (TTM)
-53.48%
3-year revenue growth (CAGR)
-13.46%
3-year earnings per share growth (CAGR)
-10.49%
What the Analysts think about Clene
Analyst ratings (Buy, Hold, Sell) for Clene stock.
Clene Financial Performance
Revenues and expenses
Clene Earnings Performance
Company profitability
Clene News
AllArticlesVideos
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
Accesswire·4 days ago
Clene to Present at the Emerging Growth Conference
GlobeNewsWire·2 months ago
Clene to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Clene stock?
Clene (CLNN) has a market cap of $38M as of June 13, 2025.
What is the P/E ratio for Clene stock?
The price to earnings (P/E) ratio for Clene (CLNN) stock is 0 as of June 13, 2025.
Does Clene stock pay dividends?
No, Clene (CLNN) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next Clene dividend payment date?
Clene (CLNN) stock does not pay dividends to its shareholders.
What is the beta indicator for Clene?
Clene (CLNN) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.